Multiplex Assay Kit for Peroxiredoxin 2 (PRDX2) ,etc. by FLIA (Flow Luminescence Immunoassay)

PRP; NKEFB; PRXII; TDPX1; TSA; Thioredoxin-Dependent Peroxide Reductase 1; Thiol-Specific Antioxidant 1; Natural Killer-Enhancing Factor B; Thioredoxin Peroxidase 1; Torin

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Peroxiredoxin 2 (PRDX2) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Peroxiredoxin 2 (PRDX2) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Peroxiredoxin 2 (PRDX2) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Peroxiredoxin 2 (PRDX2) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 93-105 101
EDTA plasma(n=5) 88-101 93
heparin plasma(n=5) 78-101 84
sodium citrate plasma(n=5) 89-103 95

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Peroxiredoxin 2 (PRDX2) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Peroxiredoxin 2 (PRDX2) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Peroxiredoxin 2 (PRDX2) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 91-103% 96-105% 80-90% 99-105%
EDTA plasma(n=5) 93-101% 89-103% 97-105% 86-94%
heparin plasma(n=5) 78-95% 80-95% 80-96% 82-103%
sodium citrate plasma(n=5) 86-98% 94-103% 83-101% 80-88%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:PRDX2) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Free Radical Research Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress Pubmed:25564095
PLoS One Differences in Proinflammatory Property of Six Subtypes of Peroxiredoxins and Anti-Inflammatory Effect of Ligustilide in Macrophages pubmed:27716839
Experiental And Therapeutic Medicine Plasma proteins as potential targets of abnormal Savda syndrome in asthma patients treated with unique Uighur prescription pubmed:28672924
Oncotarget Neuroprotective effect of a novel gastrodin derivative against ischemic brain injury: involvement of peroxiredoxin and TLR4 signaling inhibition pubmed:29207618
European Journal of Applied Physiology Prolonged forearm ischemia attenuates endothelium-dependent vasodilatation and plasma nitric oxide metabolites in overweight middle-aged men Pubmed:29785503
Journal of Applied Physiology Montmorency cherry supplementation attenuates vascular dysfunction induced by prolonged forearm occlusion in overweight middle-aged men Pubmed: 30496705
ACS Omega SOD1 is a Possible Predictor of COVID-19 Progression as Revealed by Plasma Proteomics 34250342
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPF757Hu02 Recombinant Peroxiredoxin 2 (PRDX2) Positive Control; Immunogen; SDS-PAGE; WB.
RPF757Hu03 Recombinant Peroxiredoxin 2 (PRDX2) Positive Control; Immunogen; SDS-PAGE; WB.
RPF757Hu01 Recombinant Peroxiredoxin 2 (PRDX2) Positive Control; Immunogen; SDS-PAGE; WB.
PAF757Hu01 Polyclonal Antibody to Peroxiredoxin 2 (PRDX2) WB; IHC; ICC; IP.
PAF757Hu03 Polyclonal Antibody to Peroxiredoxin 2 (PRDX2) WB; IHC; ICC; IP.
PAF757Hu02 Polyclonal Antibody to Peroxiredoxin 2 (PRDX2) WB; IHC; ICC; IP.
MAF757Hu23 Monoclonal Antibody to Peroxiredoxin 2 (PRDX2) WB; IHC; ICC; IP.
MAF757Hu21 Monoclonal Antibody to Peroxiredoxin 2 (PRDX2) WB
WEF757Hu Wide-range ELISA Kit for Peroxiredoxin 2 (PRDX2) Enzyme-linked immunosorbent assay for Antigen Detection.
SEF757Hu ELISA Kit for Peroxiredoxin 2 (PRDX2) Enzyme-linked immunosorbent assay for Antigen Detection.
LMF757Hu Multiplex Assay Kit for Peroxiredoxin 2 (PRDX2) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.